Suven Life Sciences Limited has informed the Exchange regarding Investor Presentation
SUVEN Life Sciences
Communication to investors Mar 2019
25-May-19
2018-19 Q4 results
Risk statement
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.
25-May-19
2018-19 Q4 results
FINANCIAL QUICK VIEW Quarter 4 – Mar 2019
• Growth in income • Growth in Pre-R&D EBIDTA • Growth in EBIDTA • Growth in PAT • R&D cost on revenue • Increase in R&D costs
90.72% 129.13% 163.66% 170.41% 6.95% 27.35%
25-May-19
2018-19 Q4 results
FINANCIAL QUICK VIEW Year ending – Mar 2019
• Growth in income • Growth in Pre-R&D EBIDTA • Growth in EBIDTA • Growth in PAT • R&D cost on revenue • Increase in R&D costs
6.05% -2.10% -3.29% -5.20% 8.76% 3.09%
25-May-19
2018-19 Q4 results
MAJOR PROFITABILITY RATIOS
Q4 Mar 19
FY Mar 19
49.37%
44.79%
42.42%
36.03%
26.47%
21.80%
28.60%
25.02%
Pre-R&D EBITDA to Income
EBIDTA to Income
PAT to Income
Cash Flow to Income
25-May-19
2018-19 Q4 results
Q4 to Q3 COMPARISON
Current quarter to previous quarter
Revenue - INR Million
PAT - INR Million
3,100.00
2,600.00
2,100.00
1,600.00
1,100.00
600.00
100.00
1,200.00
1,000.00
800.00
600.00
400.00
200.00
-
2,570.53
1,347.83
680.47
251.65
800.00 700.00 600.00 500.00 400.00 300.00 200.00 100.00 -
Q3 Dec 18
Q4 Mar 19
Q3 Dec 18
Q4 Mar 19
EBIDTA - INR Million
Pre-R&D EBIDTA - INR Million
1,090.48
413.59
1,269.17
553.90
1,450.00
1,250.00
1,050.00
850.00
650.00
450.00
250.00
50.00
Q3 Dec 18
Q4 Mar 19
Q3 Dec 18
Q4 Mar 19
25-May-19
2018-19 Q4 results
INCOME COMPARISON
Year on year
INR Million
6,485.29
6,877.34
2,229.49
2,570.53
8,000.00
7,000.00
6,000.00
5,000.00
4,000.00
3,000.00
2,000.00
1,000.00
-
Q4 Mar 18
Q4 Mar 19
FY Mar 18
FY Mar 19
25-May-19
2018-19 Q4 results
PROFIT COMPARISON
Year on year
INR Million
1,581.51
1,499.25
623.07
680.47
1,800.00
1,600.00
1,400.00
1,200.00
1,000.00
800.00
600.00
400.00
200.00
-
Q4 Mar 18
Q4 Mar 19
FY Mar 18
FY Mar 19
25-May-19
2018-19 Q4 results
EBIDTA COMPARISON
Year on year
INR Million
2,561.87
2,477.71
1,004.68
1,090.48
3,000.00
2,500.00
2,000.00
1,500.00
1,000.00
500.00
-
Q4 Mar 18
Q4 Mar 19
FY Mar 18
FY Mar 19
25-May-19
2018-19 Q4 results
R & D – EXPENDITURE
Year on year
INR Million
584.67
602.76
169.15
178.69
700.00
600.00
500.00
400.00
300.00
200.00
100.00
-
Q4 Mar 18
Q4 Mar 19
FY Mar 18
FY Mar 19
25-May-19
2018-19 Q4 results
PRE-R&D EBIDTA
Year on year
INR Million
3,146.53
3,080.47
1,173.83
1,269.17
3,500.00
3,000.00
2,500.00
2,000.00
1,500.00
1,000.00
500.00
-
Q4 Mar 18
Q4 Mar 19
FY Mar 18
FY Mar 19
25-May-19
2018-19 Q4 results
PRE-R&D CASHFLOW
Year on year
INR Million
2,379.27
2,323.42
2,500.00
2,000.00
1,500.00
1,000.00
845.84
913.79
500.00
-
Q4 Mar 18
Q4 Mar 19
FY Mar 18
FY Mar 19
25-May-19
2018-19 Q4 results
Financial Snapshot
All figures are in INR Million, other than ratios and EPS
Standalone
Consolidated
Q4 - FY19 Q3 - FY19 Q4 - FY18
2018-19
2017-18
2018-19
2017-18
Income Pre-R&D EBITDA
2,571 1,269
1,348 554
2,229 1,174
6,877 3,080
6,485 3,147
6,877 3,045
6,485 3,117
Pre-R&D EBITDA Margin EBITDA EBITDA Margin EBIT EBIT Margin Financing costs Taxes Taxes to Profit Net Profit after tax NP Margin
EPS (basic & diluted not annualised)
Paid up share capital (One Rupee Share) Depreciation R&D expenses
49.37% 1,090 42.42% 1,037 40.32% 16 340 33.34% 680 26.47%
41.10% 414 30.69% 357 26.47% 5 100 28.41% 252 18.67%
52.65% 1,005 45.06% 949 42.57% 13 313 33.47% 623 27.95%
44.79% 2,478 36.03% 2,255 32.79% 38 718 32.38% 1,499 21.80%
48.52% 2,562 39.50% 2,346 36.17% 46 718 31.24% 1,582 24.39%
44.28% 1,847 26.85% 1,624 23.61% 38 718
48.06% 2,215 34.15% 1,999 30.82% 46 718
868 12.62%
1,234 19.03%
5.34
1.98
4.91
11.79
12.45
6.83
9.72
127 55 179
127 56 140
127 54 169
127 221 603
127 213 585
127 221 1,199
127 213 902
On consolidation of the accounts of Suven Neurosciences, Inc., USA, the wholly owned subsidiary, the PAT reduced to INR 868 Mn and expenditure on R&D increased to INR 1199 Mn..
25-May-19
2018-19 Q4 results
News Release
• Marupirdine (SUVN-502) Phase 2A clinical trial, indicated for
patients with moderate Alzheimer’s initiated in 76 investigator sites in USA and completed clinical trial with the last patient last visit (LPLV) in May 2019.
• Top-line Phase 2A data for Masupirdine (SUVN-502) is on track to
be presented at Alzheimer’s Association International Conference at Los Angeles on 17th July 2019.
• During the period Suven secures 12 product patents in Eurasia, Europe, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Korea.
• Suven invested through Suven Pharma, Inc., taking minority stake in
Shore Suven Pharma, Inc., USA.
25-May-19
2018-19 Q4 results